Earnings Call Summary | Journey Medical(DERM.US) Q1 2024 Earnings Conference
Earnings Call Summary | Journey Medical(DERM.US) Q1 2024 Earnings Conference
The following is a summary of the Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript:
以下是Journey Medical Corporation（DERM）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Journey Medical reported Q1 revenue of $13 million, a 7% increase year-over-year, with Qbrexza and Accutane contributing over $10.8 million. The company realized significant reduction in SG&A expenses and achieved profitability in Q1. Over 90% of the company's revenue comes from Qbrexza, Accutane, Amzeeq, and Zilxi. The company's cash resources reached $24.1 million at the end of Q1 2024.
Journey Medical報告稱，第一季度收入爲1300萬美元，同比增長7％，其中Qbrexza和Accutane的收入超過1,080萬美元。該公司大幅減少了銷售和收購費用，並在第一季度實現了盈利。該公司90％以上的收入來自Qbrexza、Accutane、Amzeeq和Zilxi。截至2024年第一季度末，該公司的現金資源達到2410萬美元。
Business Progress:
業務進展：
Qbrexza and Accutane gained market share, expected to drive growth throughout 2024. Journey Medical is preparing to launch DFD-29 for Rosacea treatment following positive Phase 3 trial results. The FDA has accepted the new drug application for DFD-29, with a planned date in November. The company is exploring opportunities to out-license its IP and acquire or in-license FDA-approved products. The company expects net revenues in the range of $55 to $60 million by the year-end.
Qbrexza和Accutane增加了市場份額，預計將推動整個2024年的增長。在 3 期試驗結果呈陽性之後，Journey Medical 正準備推出用於酒渣鼻治療的 DFD-29。美國食品藥品管理局已經接受了 DFD-29 的新藥申請，計劃於11月提交。該公司正在探索向外許可其知識產權以及收購或獲得美國食品藥品管理局批准的產品許可的機會。該公司預計，到年底，淨收入將在5,500萬美元至6000萬美元之間。
More details: Journey Medical IR
更多詳情： 旅程醫療 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。